Bruno M. de Brito Robalo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bruno M. de Brito Robalo has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Youssef Ali Amer
E-MEDIA, STADIUS, Department of Electrical Engineering (ESAT), Campus Group T, KU Leuven, 3000 Leuven, Belgium
2 shared publications - Alberto Gutierrez-Torre
Barcelona Supercomputing Center, Barcelona, Spain
2 shared publications - Anne E M Leenders
Princess Máxima Center for Pediatric Oncology , Utrecht
2 shared publications - Antti Airola
University of Turku
2 shared publications - Christophe Maes
The European Institute for Innovation Through Health Data, Oosterzele, Belgium
2 shared publications - Christos Chatzichristos
STADIUS Center for Dynamical Systems, Signal Processing, and Data Analytics, Department of Electrical Engineering, KU Leuven, Leuven, Belgium
2 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (5)
Cohort Profile Update: the Rotterdam Periconceptional Cohort—biomarkers, lifestyle intervention, and artificial intelligence
- 18 August 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (5)
Open AccessCohort Profile Update: the Rotterdam Periconceptional Cohort—biomarkers, lifestyle intervention, and artificial intelligence
- Open Access
- 25 September 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (2) , 394-407
Longitudinal cortical thickness changes in children with posterior fossa tumors
Background Children with posterior fossa tumors (PFTs) are at risk of long-term neurocognitive deficits, yet the impact of tumor grade and treatment intensity on cortical development remains poorly understood. The aim of this study was to determine whether cortical thickness trajectories differ between children with low- versus high-grade PFTs and whether radiation dose influences cortical development in medulloblastoma patients. Methods: We conducted a retrospective longitudinal study of 55 children (37 low-grade, 18 high-grade medulloblastoma) diagnosed between 2018 and 2020. A total of 406 T1-weighted MRI scans acquired up to five years post-diagnosis were processed using CAT12 in SPM12 to estimate cortical thickness. Vertex-wise linear mixed-effects models assessed cortical thickness changes over time, adjusting for age at diagnosis, sex, and hydrocephalus. Within the high-grade group, we evaluated the effect of craniospinal irradiation (CSI) dose (23.4 vs. ≥36 Gy) on cortical development. Results: Children with low-grade tumors showed significant bilateral cortical thinning over time, consistent with typical neurodevelopment. In contrast, medulloblastoma patients treated with surgery, chemotherapy, and radiation therapy showed relative cortical stability across follow-up. Significant group-by-time interactions were observed, with low-grade patients demonstrating greater cortical thinning in parietal, temporal, and occipital regions. No significant differences in cortical trajectories were found between high- and standard-dose CSI subgroups. Conclusions: Cortical development trajectories in pediatric PFT survivors differ by tumor grade and treatment intensity. While low-grade patients exhibit expected maturational thinning, cortical stability in high-grade patients may reflect disrupted neurodevelopment. These findings underscore the need for longitudinal neuroimaging in pediatric neuro-oncology survivorship care.
- 25 September 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (2) , 394-407
Open AccessLongitudinal cortical thickness changes in children with posterior fossa tumors
Background Children with posterior fossa tumors (PFTs) are at risk of long-term neurocognitive deficits, yet the impact of tumor grade and treatment intensity on cortical development remains poorly understood. The aim of this study was to determine whether cortical thickness trajectories differ between children with low- versus high-grade PFTs and whether radiation dose influences cortical development in medulloblastoma patients. Methods: We conducted a retrospective longitudinal study of 55 children (37 low-grade, 18 high-grade medulloblastoma) diagnosed between 2018 and 2020. A total of 406 T1-weighted MRI scans acquired up to five years post-diagnosis were processed using CAT12 in SPM12 to estimate cortical thickness. Vertex-wise linear mixed-effects models assessed cortical thickness changes over time, adjusting for age at diagnosis, sex, and hydrocephalus. Within the high-grade group, we evaluated the effect of craniospinal irradiation (CSI) dose (23.4 vs. ≥36 Gy) on cortical development. Results: Children with low-grade tumors showed significant bilateral cortical thinning over time, consistent with typical neurodevelopment. In contrast, medulloblastoma patients treated with surgery, chemotherapy, and radiation therapy showed relative cortical stability across follow-up. Significant group-by-time interactions were observed, with low-grade patients demonstrating greater cortical thinning in parietal, temporal, and occipital regions. No significant differences in cortical trajectories were found between high- and standard-dose CSI subgroups. Conclusions: Cortical development trajectories in pediatric PFT survivors differ by tumor grade and treatment intensity. While low-grade patients exhibit expected maturational thinning, cortical stability in high-grade patients may reflect disrupted neurodevelopment. These findings underscore the need for longitudinal neuroimaging in pediatric neuro-oncology survivorship care.
- Open Access
- 1 September 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e83369
Rethinking Trust in Synthetic Health Data: Lessons from Seven European Research Initiatives (Preprint)
Synthetic data generation (SDG) structured health data is increasingly promoted as a solution to longstanding barriers in health data access. It is offering the promise of privacy-preserving data reuse for research, innovation, and policy. Despite rapid technical advances, the adoption of synthetic health data in real-world settings remains limited. Shaped by challenges around data quality, representativeness, infrastructure readiness, trust, and legal uncertainty, this viewpoint draws on experiences from 7 European research initiatives within the HealthData4EU cluster to reflect on how SDG is being operationalized in practice. It synthesizes cross-project insights to highlight recurring methodological and governance tensions and to examine their implications for trust and responsible use. The analysis argues that trustworthy SDG cannot be achieved through technical optimization alone but requires alignment between evaluation practices, upstream data stewardship, regulatory clarity, and sustained stakeholder engagement. Addressing these conditions is essential for moving synthetic data from experimental pilots toward a credible and sustainable component of European health research ecosystems.
- 1 September 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e83369
Open AccessRethinking Trust in Synthetic Health Data: Lessons from Seven European Research Initiatives (Preprint)
Synthetic data generation (SDG) structured health data is increasingly promoted as a solution to longstanding barriers in health data access. It is offering the promise of privacy-preserving data reuse for research, innovation, and policy. Despite rapid technical advances, the adoption of synthetic health data in real-world settings remains limited. Shaped by challenges around data quality, representativeness, infrastructure readiness, trust, and legal uncertainty, this viewpoint draws on experiences from 7 European research initiatives within the HealthData4EU cluster to reflect on how SDG is being operationalized in practice. It synthesizes cross-project insights to highlight recurring methodological and governance tensions and to examine their implications for trust and responsible use. The analysis argues that trustworthy SDG cannot be achieved through technical optimization alone but requires alignment between evaluation practices, upstream data stewardship, regulatory clarity, and sustained stakeholder engagement. Addressing these conditions is essential for moving synthetic data from experimental pilots toward a credible and sustainable component of European health research ecosystems.
- Open Access
- 1 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Building Trust in Synthetic Health Data: Methodological and Acceptance Challenges across Seven European Projects (Preprint)
BACKGROUND Synthetic data generation (SDG) is increasingly used in health research to address privacy concerns and data sharing barriers, particularly in cross-border and multi-institutional contexts. Despite growing interest, questions remain around the methodological soundness, legal status, and real-world trustworthiness of synthetic health data. OBJECTIVE This paper examines how SDG is operationalized across seven European projects in the HealthData4EU cluster. It identifies common methodological, compliance, and acceptance challenges, and highlights emerging strategies to ensure the quality and utility of synthetic health data. METHODS A qualitative multiple case study approach was used, combining workshop presentations with structured input from each project. Projects were analyzed across four aspects: methodological challenges, data quality assurance, trust and transparency strategies, and contributions to the wider synthetic data ecosystem. RESULTS Results reveal recurring challenges across projects: tension between privacy and utility, lack of shared quality validation standards, institutional readiness gaps, and legal ambiguity under GDPR. Projects employ varied strategies, including federated machine learning and validation pipelines, differential privacy, co-design processes, and metadata transparency tools, but implementation remains uneven. The absence of harmonised legal and evaluation frameworks continues to hinder broader uptake. CONCLUSIONS To scale SDG from isolated pilots to trusted European infrastructure, four priorities are critical: shared evaluation metrics, legal clarity, sustainable platforms, and embedded stakeholder engagement. While rooted in specific projects, the insights offer broader relevance for global SDG efforts, as the core tensions identified are likely to recur across health systems.
- 1 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessBuilding Trust in Synthetic Health Data: Methodological and Acceptance Challenges across Seven European Projects (Preprint)
BACKGROUND Synthetic data generation (SDG) is increasingly used in health research to address privacy concerns and data sharing barriers, particularly in cross-border and multi-institutional contexts. Despite growing interest, questions remain around the methodological soundness, legal status, and real-world trustworthiness of synthetic health data. OBJECTIVE This paper examines how SDG is operationalized across seven European projects in the HealthData4EU cluster. It identifies common methodological, compliance, and acceptance challenges, and highlights emerging strategies to ensure the quality and utility of synthetic health data. METHODS A qualitative multiple case study approach was used, combining workshop presentations with structured input from each project. Projects were analyzed across four aspects: methodological challenges, data quality assurance, trust and transparency strategies, and contributions to the wider synthetic data ecosystem. RESULTS Results reveal recurring challenges across projects: tension between privacy and utility, lack of shared quality validation standards, institutional readiness gaps, and legal ambiguity under GDPR. Projects employ varied strategies, including federated machine learning and validation pipelines, differential privacy, co-design processes, and metadata transparency tools, but implementation remains uneven. The absence of harmonised legal and evaluation frameworks continues to hinder broader uptake. CONCLUSIONS To scale SDG from isolated pilots to trusted European infrastructure, four priorities are critical: shared evaluation metrics, legal clarity, sustainable platforms, and embedded stakeholder engagement. While rooted in specific projects, the insights offer broader relevance for global SDG efforts, as the core tensions identified are likely to recur across health systems.
- Open Access
- 1 January 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 6 (1) , vdae026
Unraveling the relations between post-traumatic stress symptoms, neurocognitive functioning, and limbic white matter in pediatric brain tumor patients
Pediatric brain tumor patients are at risk of developing neurocognitive impairments and associated white matter alterations. In other populations, post-traumatic stress symptoms (PTSS) impact cognition and white matter. This study aims to investigate the effect of PTSS on neurocognitive functioning and limbic white matter in pediatric brain tumor patients. Sixty-six patients (6–16 years) completed neuropsychological assessment and brain MRI (1-year post-diagnosis) and parents completed PTSS proxy questionnaires (CRIES-13; 1–3 months and 1-year post-diagnosis). Mean Z-scores and percentage impaired (>1SD) for attention, processing speed, executive functioning, and memory were compared to normscores (t-tests, chi-square tests). Multi-shell diffusion MRI data were analyzed for white matter tractography (fractional anisotropy/axial diffusivity). Effects of PTSS on neurocognition and white matter were explored with linear regression models (FDR correction for multiple testing), including age at diagnosis, treatment intensity, and tumor location as covariates. Neurocognition and limbic white matter associations were explored with correlations. Attention (M = −0.49, 33% impaired; P < .05) and processing speed (M = −0.57, 34% impaired; P < .05) were significantly lower than healthy peers. PTSS was associated with poorer processing speed (β = −0.64, P < .01). Treatment intensity, age at diagnosis, and tumor location, but not PTSS, were associated with limbic white matter metrics. Neurocognition and white matter metrics were not associated. Higher PTSS was associated with poorer processing speed, highlighting the need for monitoring, and timely referrals to optimize psychological well-being and neurocognitive functioning. Future research should focus on longitudinal follow-up and explore the impact of PTSS interventions on neurocognitive performance.
- 1 January 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 6 (1) , vdae026
Open AccessUnraveling the relations between post-traumatic stress symptoms, neurocognitive functioning, and limbic white matter in pediatric brain tumor patients
Pediatric brain tumor patients are at risk of developing neurocognitive impairments and associated white matter alterations. In other populations, post-traumatic stress symptoms (PTSS) impact cognition and white matter. This study aims to investigate the effect of PTSS on neurocognitive functioning and limbic white matter in pediatric brain tumor patients. Sixty-six patients (6–16 years) completed neuropsychological assessment and brain MRI (1-year post-diagnosis) and parents completed PTSS proxy questionnaires (CRIES-13; 1–3 months and 1-year post-diagnosis). Mean Z-scores and percentage impaired (>1SD) for attention, processing speed, executive functioning, and memory were compared to normscores (t-tests, chi-square tests). Multi-shell diffusion MRI data were analyzed for white matter tractography (fractional anisotropy/axial diffusivity). Effects of PTSS on neurocognition and white matter were explored with linear regression models (FDR correction for multiple testing), including age at diagnosis, treatment intensity, and tumor location as covariates. Neurocognition and limbic white matter associations were explored with correlations. Attention (M = −0.49, 33% impaired; P < .05) and processing speed (M = −0.57, 34% impaired; P < .05) were significantly lower than healthy peers. PTSS was associated with poorer processing speed (β = −0.64, P < .01). Treatment intensity, age at diagnosis, and tumor location, but not PTSS, were associated with limbic white matter metrics. Neurocognition and white matter metrics were not associated. Higher PTSS was associated with poorer processing speed, highlighting the need for monitoring, and timely referrals to optimize psychological well-being and neurocognitive functioning. Future research should focus on longitudinal follow-up and explore the impact of PTSS interventions on neurocognitive performance.